
    
      The Phase 3 study is to confirm the efficacy of OTL38 in combination with fluorescent light
      to detect additional Folate Receptor-positive (FR+) ovarian cancer lesions not detected by
      palpation and visualization under normal light in patients with FR+ ovarian cancer scheduled
      to undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer
      surgery
    
  